why choose us

300×250 Ad Slot

Drug FDA Status

Showing 30 of 185 result(s) (Page 3 of 19)
Drug Name: Hepcludex

Active Ingredient: bulevirtide-gmod

Approval Date: 2026-05-22

Description: To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis

Drug Name: Baxfendy

Active Ingredient: baxdrostat

Approval Date: 2026-05-15

Description: To treat hypertension in combination with other antihypertensive drugs

Drug Name: Beqalzi

Active Ingredient: sonrotoclax

Approval Date: 2026-05-13

Description: To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor

Drug Name: Veppanu

Active Ingredient: vepdegestrant

Approval Date: 2026-05-01

Description: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

Drug Name: Idvynso

Active Ingredient: doravirine and islatravir

Approval Date: 2026-04-20

Description: To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine

Drug Name: Foundayo

Active Ingredient: orforglipron

Approval Date: 2026-04-01

Description: To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity

Drug Name: Awiqli

Active Ingredient: insulin icodec-abae

Approval Date: 2026-03-26

Description: To improve glycemic control in adults with type 2 diabetes mellitus

Drug Name: Lifyorli

Active Ingredient: relacorilant

Approval Date: 2026-03-25

Description: To treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens, at least one of which included bevacizumab

Drug Name: Avlayah

Active Ingredient: tividenofusp alfa-eknm

Approval Date: 2026-03-24

Description: To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)

Drug Name: Lynavoy

Active Ingredient: linerixibat

Approval Date: 2026-03-17

Description: To treat cholestatic pruritus associated with primary biliary cholangitis

300×250 Ad Slot